Bristol Myers Squibb

For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been
Fierce Pharma
Mon, 10/7/24 - 11:16 am
Bristol Myers Squibb
KarXT
Cobenfy
schizophrenia
BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval
Fierce Pharma
Thu, 10/3/24 - 10:25 pm
Bristol Myers Squibb
Opdivo
FDA
non-small cell lung cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Wed, 10/2/24 - 11:24 am
FDA
Bridge Bio
acoramidis
AstraZeneca
Daiichi Sankyo
Dato-DXd
Vertex Pharmaceuticals
Vanza Triple
PTC Therapeutics
Upstaza
Bristol Myers Squibb
Opdivo
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Reuters
Tue, 10/1/24 - 09:59 am
Bristol Myers Squibb
Celgene
Breyanzi
legal
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Medical Marketing and Media
Mon, 09/30/24 - 09:28 am
Bristol Myers Squibb
FDA
schizophrenia
Cobenfy
FDA eyes first schizophrenia drug shift in decades
Axios
Thu, 09/26/24 - 11:02 am
Bristol Myers Squibb
FDA
KarXT
schizophrenia
Cancer and diabetes drugs expected to dominate 2025 Medicare negotiations under IRA
BioSpace
Wed, 09/25/24 - 12:08 pm
Inflation Reduction Act
CMS
drug pricing
Pfizer
Merck
Bristol Myers Squibb
cancer
diabetes
2seventy Bio stops enrolling patients in blood cancer therapy study
Reuters
Wed, 09/25/24 - 11:56 am
2seventy bio
Bristol Myers Squibb
Multiple Myeloma
cell therapy
Abecma
clinical trials
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on
Fierce Pharma
Sun, 09/22/24 - 09:34 pm
Bristol Myers Squibb
layoffs
New Jersey
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Fierce Biotech
Mon, 09/16/24 - 09:44 am
Bristol Myers Squibb
Immatics
bispecifics
IMA401
ESMO
3 FDA approval dates to watch in the year’s final push
Pharma Voice
Wed, 09/11/24 - 11:39 am
FDA
Bristol Myers Squibb
KarXT
schizophrenia
Regeneron
Sanofi
Dupixent
COPD
BridgeBio
acoramidis
ATTR cardiomyopathy
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO
Reuters
Fri, 09/6/24 - 10:54 am
Zenas BioPharma
IPOs
Bristol Myers Squibb
obexelimab
ArsenalBio raises $325M in one of the year’s largest biotech funding rounds
BioPharma Dive
Wed, 09/4/24 - 11:46 am
Arsenal Bio
funding
biotech
cell therapy
ovarian cancer
kidney cancer
Roche
Bristol Myers Squibb
FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds
Fierce Pharma
Fri, 08/23/24 - 10:55 am
FDA
stomach cancer
Bristol Myers Squibb
Opdivo
Yervoy
Merck
Keytruda
BeiGene
Tevimbra
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Reuters
Thu, 08/22/24 - 10:01 pm
Zenas BioPharma
IPOs
Bristol Myers Squibb
BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer
Pharmaphorum
Thu, 08/22/24 - 11:09 am
Bristol Myers Squibb
Opdivo
Yervoy
liver cancer
FDA
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
Pharma Voice
Mon, 08/19/24 - 09:58 am
Bristol Myers Squibb
KarXT
FDA
schizophrenia
AbbVie
IRA negotiations slash Medicare prices for Big Pharma blockbusters by up to 79%
Fierce Pharma
Thu, 08/15/24 - 11:55 am
Medicare
drug pricing
Inflation Reduction Act
JNJ
Xarelto
Imbruvica
Stelara
Bristol Myers Squibb
Eliquis
Eli Lilly
Jardiance
Merck
Januvia
Amgen
Enbrel
AstraZeneca
Farxiga
Novo Nordisk
Fiasp
Novartis
Entresto
Pharma execs react to final drug price negotiations with Medicare
Pharma Voice
Fri, 08/9/24 - 11:21 am
Medicare
drug pricing
Inflation Reduction Act
Bristol Myers Squibb
Eli Lilly
JNJ
Bayer
Merck
AstraZeneca
Novartis
Amgen
AbbVie
Novo Nordisk
Bristol Myers cited by FDA for misleading claims on Krazati website
Seeking Alpha
Wed, 08/7/24 - 11:11 pm
Bristol Myers Squibb
FDA
OPDP
Krazati

Pages